Literature DB >> 26947522

Apolipoprotein L1 and Kidney Disease in African Americans.

David J Friedman1, Martin R Pollak2.   

Abstract

Genetic variants in the Apolipoprotein L1 (APOL1) gene cause high rates of kidney disease in African Americans. These variants, found only in individuals with recent African ancestry, confer enhanced innate immunity against African trypanosomes. Although they are among the most powerful disease-causing common variants discovered to date, we are just beginning to understand how they promote kidney injury. Since APOL1 is present in only a few primate species, much of our current knowledge has come from natural experiments in humans and in vitro studies while awaiting the development of transgenic animal models. Understanding more about the function of ApoL1 and how the high-risk variants behave differently from other ApoL1 molecules is a high priority in kidney disease research.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APOL1; African American; apolipoprotein L1; kidney disease

Mesh:

Substances:

Year:  2016        PMID: 26947522      PMCID: PMC4811340          DOI: 10.1016/j.tem.2016.02.002

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  81 in total

Review 1.  Genetics of kidney failure and the evolving story of APOL1.

Authors:  David J Friedman; Martin R Pollak
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

2.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

3.  Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene.

Authors:  P N Duchateau; C R Pullinger; M H Cho; C Eng; J P Kane
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

4.  Characterization of a novel trypanosome lytic factor from human serum.

Authors:  J Raper; R Fung; J Ghiso; V Nussenzweig; S Tomlinson
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

5.  Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.

Authors:  Xiqian Lan; Hongxiu Wen; Moin A Saleem; Joanna Mikulak; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-03-18       Impact factor: 3.362

6.  Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.

Authors:  Adrienne Tin; Morgan E Grams; Nisa M Maruthur; Brad C Astor; David Couper; Thomas H Mosley; Myriam Fornage; Rulan S Parekh; Josef Coresh; Wen Hong Linda Kao
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

7.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

8.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Authors:  Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

9.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.

Authors:  Siqin Zhaorigetu; Guanghua Wan; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  Autophagy       Date:  2008-11-23       Impact factor: 16.016

10.  Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1.

Authors:  Gilles Vanwalleghem; Frédéric Fontaine; Laurence Lecordier; Patricia Tebabi; Kristoffer Klewe; Derek P Nolan; Yoshiki Yamaryo-Botté; Cyrille Botté; Anneke Kremer; Gabriela Schumann Burkard; Joachim Rassow; Isabel Roditi; David Pérez-Morga; Etienne Pays
Journal:  Nat Commun       Date:  2015-08-26       Impact factor: 14.919

View more
  38 in total

1.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

Review 2.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

3.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

4.  Exome-Based Rare-Variant Analyses in CKD.

Authors:  Sophia Cameron-Christie; Charles J Wolock; Emily Groopman; Slavé Petrovski; Sitharthan Kamalakaran; Gundula Povysil; Dimitrios Vitsios; Mengqi Zhang; Jan Fleckner; Ruth E March; Sahar Gelfman; Maddalena Marasa; Yifu Li; Simone Sanna-Cherchi; Krzysztof Kiryluk; Andrew S Allen; Bengt C Fellström; Carolina Haefliger; Adam Platt; David B Goldstein; Ali G Gharavi
Journal:  J Am Soc Nephrol       Date:  2019-05-13       Impact factor: 10.121

5.  Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain.

Authors:  Charles Schaub; Joseph Verdi; Penny Lee; Nada Terra; Gina Limon; Jayne Raper; Russell Thomson
Journal:  J Biol Chem       Date:  2020-07-29       Impact factor: 5.157

6.  Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.

Authors:  Daniel Granado; Daria Müller; Vanessa Krausel; Etty Kruzel-Davila; Christian Schuberth; Melanie Eschborn; Roland Wedlich-Söldner; Karl Skorecki; Hermann Pavenstädt; Ulf Michgehl; Thomas Weide
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

7.  Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.

Authors:  Justin Chun; Jia-Yue Zhang; Maris S Wilkins; Balajikarthick Subramanian; Cristian Riella; Jose M Magraner; Seth L Alper; David J Friedman; Martin R Pollak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205

8.  Beyond APOL1: Genetic Inroads into Understanding Population Disparities in Diabetic Kidney Disease.

Authors:  Karl Skorecki; Walter G Wasser
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

9.  Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.

Authors:  Dominick Santoriello; Syed A Husain; Sacha A De Serres; Andrew S Bomback; Russell J Crew; Elena-Rodica Vasilescu; Geo Serban; Eric S Campenot; Krzysztof Kiryluk; Sumit Mohan; Gregory A Hawkins; Pamela J Hicks; David J Cohen; Jai Radhakrishnan; Michael B Stokes; Glen S Markowitz; Barry I Freedman; Vivette D D'Agati; Ibrahim Batal
Journal:  Kidney Int       Date:  2018-10-02       Impact factor: 10.612

Review 10.  APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?

Authors:  Opeyemi A Olabisi; John F Heneghan
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.